What is TECX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.46B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TECX?

P/E (TTM) is n/a and 52-week range is $14.81 to $39.53 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TECX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TECX?

The company profile lists net income (TTM) near $-86M, EPS (TTM) near $-4.56 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tectonic Therapeutic Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 18.9M shares outstanding, ISIN US8789721086 when available from company profile and filing metadata.

Tectonic Therapeutic Inc

$TECX

Health Care · Biotechnology

IR Run Scenarios

$23.33

+2.55%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.

Employees

Website

tectonictx.com/

IPO

2018-06-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)